Korea Research Institute of Bioscience and Biotechnology

Yungjin Pharmaceutical Co., Ltd.

Korea Institute of Bioscience and Biotechnology

Jung-hee Kim

Sei-Ryang Oh

Doo-Young Kim

Ok-Kyoung Kwon

Ji-seok Yoo

Dae-hee Shin

Byung-hwan Ryoo

Yongnam Lee

Kyung-seop Ahn

Hyeongkyu Lee

Hyuk-hwan Song

Soo Hyun Kim

Jung Weon Lee

Sangku Lee

Joongku Lee

Hyeong-Kyu Lee

Hyuk-Hwan Song

Ho-Jae Lee

Eun-Ah Kim

Soon-Ja Choi

Su-Yong Choi

Kyungseop Ahn

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract ofvarthan that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

[object Object]

A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract ofvarthan that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

The present invention relates to an anoikis-inducing agent comprising aextract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. Theextract, the tiarellic acid compound isolated therefrom or pharmaceutically acceptable salt thereof of the present invention leads to loss of cell adhesion to reduce cancer cell proliferation and exhibits the effect of inducing cell death in cancer cells expressing a tumor-associated antigen L6 or a homolog thereof, thereby being used for preventing and treating cancer diseases due to a tumor-associated antigen L6 or a homolog thereof.

Growing community of inventors

Daejeon, South Korea

Jung-hee Kim